Pipeline
Small Molecule Drug Conjugate (SMDC & ALDC)
First-in-class, Precision Guided Cancer Therapy, could replace the original drug and suitable to combine with immunotherapy.
| Drug Name | Payload/MOA/Target | Indication | Rights | Development Stage | ||||
|---|---|---|---|---|---|---|---|---|
| Pre-clinical | IND | Phase I | Phase II | Phase III | ||||
Tumor MicroEnvironment Activated Small Molecule Drug Conjugates (TMEA-ALDC & TMEA-SMDC)
| Drug Name | Payload/MOA/Target | Indication | Rights | Pre-clinical | IND | Phase I | Phase II | Phase III |
|
QHL-108 (Legubicin) |
Doxorubicin | Soft Tissue Sarcoma | Global | |||||
|---|---|---|---|---|---|---|---|---|
| Lung Adenocarcinoma | Global | |||||||
| Ovarian Cancer | Global |
|
QHL-236 (Legutaxel) |
Paclitaxel | Solid Tumor | Global | |||||
|---|---|---|---|---|---|---|---|---|
| Bladder Cancer | Global |
| QHL-1618 | DXd | Solid Tumor | Ex-Greater China |
|---|
| QHL-1231 | AXL/VEGF/cMET Multikinase Inhibitor | Solid Tumor | Global |
|---|
| QHL-1031 | TLR7/8 Agonist | Solid Tumor | Global |
|---|
| QHL-1096 | TLR7/8-DXd | Solid Tumor | Global |
|---|
| QHL-923 | Eribulin | Solid Tumor | Global |
|---|
| QHL-506 | PARPi | Solid Tumor | Global |
|---|
| QHL-339 | Platinum | Solid Tumor | Global |
|---|
| QHL-625 | CDK4/6 | Solid Tumor | Global |
|---|
| QHL-816 | STING Agonist | Solid Tumor | Global |
|---|
Registrational Clinical Trial
Biologics Conjugate
Best-In-Class Biologics including conjugate cytokines, antibodies, fusion proteins, and ADCs to create new generation drugs.
| Drug Name | Payload/MOA/Target | Indication | Rights | Development Stage | ||||
|---|---|---|---|---|---|---|---|---|
| Pre-clinical | IND | Phase I | Phase II | Phase III | ||||
Tumor MicroEnvironment Activated Antibodies (TMEAbody & TMEA-ICE), Cytokines and Fusion Proteins (TMEAkine)
| Drug Name | Payload/MOA/Target | Indication | Rights | Pre-clinical | IND | Phase I | Phase II | Phase III |
| IMD-101 | IL-2 | Solid Tumor | Global |
|---|
| IMD-303 | CTLA-4 | Solid Tumor | Global |
|---|
| IMD-1005 | CD47 | Solid Tumor | Global |
|---|
| IMD-2816 | CDH17-CD3 | Solid Tumor | Global |
|---|
| IMD-1112 | CLDN18.2-CD3 | Solid Tumor | Global |
|---|
| IMD-1618 | CLDN6-CD3 | Solid Tumor | Global |
|---|
| IMD-917 | DLL3-CD3 | Solid Tumor | Global |
|---|
| IMD-511 | HER2-CD3 | Solid Tumor | Global |
|---|
Tumor MicroEnvironment Activated ADCs (TMEA-ADC)
| Drug Name | Payload/MOA/Target | Indication | Rights | Pre-clinical | IND | Phase I | Phase II | Phase III |
| IMD-1628 | CLND6-TMEAlinker-DXd-TLR7/8 | Solid Tumor | Global |
|---|
| IMD-2109 | PDL1-TMEAlinker-TLR7/8 | Solid Tumor | Global |
|---|
| IMD-2358 | ROR1-TMEAlinker-DXd-TLR7/8 | Solid Tumor | Global |
|---|
| IMD-2113 | EGFR-TROP2-TMEAlinker-DXd-TLR7/8 | Solid Tumor | Global |
|---|
| IMD-2128 | EGFR-cMET-TMEAlinker-Eribulin | Solid Tumor | Global |
|---|
| IMD-2329 | DLL3-B7H3-TMEAlinker-DXd-TLR7/8 | Solid Tumor | Global |
|---|
| IMD-2101 | HER2 (ADC) | Solid Tumor | Global |
|---|
| IMD-2316 | DLL3 (ADC) | Solid Tumor | Global |
|---|
| IMD-2206 | LY6G6D (ADC) | Solid Tumor | Global |
|---|
| IMD-2408 | CCR8 (ADC) | Solid Tumor | Global |
|---|
| IMD-2503 | SSTR2 (ADC) | Solid Tumor | Global |
|---|
| IMD-2739 | GCC (ADC) | Solid Tumor | Global |
|---|
| IMD-1135 | CLDN18.2 (ADC) | Solid Tumor | Global |
|---|
Partners
| Product (Partners) | Molecule | Rights | Development Stage | ||||
|---|---|---|---|---|---|---|---|
| Pre-clinical | IND | Phase I | Phase II | Phase III | |||
| Product (Partners) | Molecule | Rights | Pre-clinical | IND | Phase I | Phase II | Phase III |
|
I-MAB
|
Confidential | Global |
Confidential
|
|---|
|
Anglikang Pharmaceutical
|
QHL-1618 TMEA-DXd | Greater China |
|---|
|
Partner |
TMEAbody Platform | Global |
|---|
|
Partner |
TMEA-SMDC Platform | Global |
|---|
* Partners and collaborative details are not fully disclosed due to commercial sensitivity